ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

perflutren

Also written as “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, “DEFINITY®” and “Perflutren Lipid Microsphere Injectable Suspension”.

Its studies are mostly in Heart Diseases · Coronary Artery Disease · Pulmonary Heart Disease · Cardiovascular Diseases · Ischemic Stroke, led by 3 companies.

Drug pagePerflutren: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 9, 20059 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheus50 open or runningphase 4since Sep 9, 2005Sep 9, 2005none ahead
Trust Bio-sonicsits history only32 open or runningphase 3since Jan 21, 2025Nov 6, 2019Feb 2027phase 3 · NCT06815627
ImaRx Therapeuticsits history only10 open or runningphase 2since Jul 25, 2007Jul 25, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lantheus only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2005First study: phase 4 study in Coronary Artery DiseaseFirst studyNCT00162370 · 400 enrolled · United States
  2. Feb 20, 2008Phase 4 study in Cardiovascular DiseasesNCT00625365 · 1,060 enrolled · United States
  3. Jun 4, 2009Phase 4 study in Pulmonary Heart DiseaseNCT00918866 · 32 enrolled · United States
  4. Jun 6, 2018Phase 3 study in Heart DiseasesNCT03571672 · 153 enrolled · United States
  5. Sep 28, 2018Phase 3 study in Heart DiseasesNCT03719612 · 160 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 Lantheus leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03719612Heart Diseases · United States3CompletedJan 9, 2020160
NCT03571672Heart Diseases · United States3CompletedAug 30, 2019153
NCT00918866Pulmonary Heart Disease · United States4CompletedDec 200932
NCT00625365Cardiovascular Diseases · United States4CompletedMay 20091,060
NCT00162370Coronary Artery Disease · United States4CompletedSep 2012400

How it is read

Names in the registry

  • “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, 3 entries
  • “DEFINITY®”, 2 entries
  • “Perflutren Lipid Microsphere Injectable Suspension”, 1 entry
  • “DEFINITY”, 1 entry
  • “Definity”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.